Patrick Lin - 01 Jan 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Business - Strategy Off
Issuer ticker: PCSA
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 17:07:34 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 04 Feb 2026.

Key facts

This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 17:07.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001799363 Primary reporting owner

Relationship: Chief Business - Strategy Off
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact
Signature date: 04 Feb 2026

Shares, units, or other non-derivative securities reported in this filing.

PCSA transaction

Options Exercise

PCSA holding

No transaction description listed

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Options Exercise

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Distribution of vested restricted shares.